NKGen Announces Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023 13:05 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous,...
NKGen Biotech to Participate in Truist Securities Cell Therapy Symposium
June 21, 2022 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell...
NKGen Biotech To Present SNK01 Clinical Data at the 2022 ASCO Annual Meeting
May 26, 2022 17:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech Inc., a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
NKGen Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting
May 05, 2022 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech Inc., a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
NKGen Biotech Announces Three SNK01 Abstracts to be Presented at the 2022 ASCO Annual Meeting
May 02, 2022 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- NKGen Biotech Inc., a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
NKGen Biotech Announces Positive SNK01 Clinical Trial Results Presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
November 15, 2021 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- NKGen Biotech, a subsidiary of NKMax, harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
NKGen Biotech Announces Acceptance of SNK01 Abstract for Presentation at the 2021 Connective Tissue Oncology Society Annual Meeting
October 20, 2021 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
NKGen Biotech to Participate in the Virtual Solebury Trout Fall Private Company Showcase Co-hosted with BMO
October 07, 2021 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell...
NKMax Announces SNK01 Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
October 04, 2021 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NKMax, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies,...
NKGen Biotech Announces Appointment of Steven Cha, MD as Chief Medical Officer
April 15, 2021 08:30 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...